Form 6-K NOVARTIS AG For: Oct 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as higher yields and oil prices flag inflation risk
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
Novartis Q3 preview: BofA sees strong product momentum, potential EBIT Upgrade
October 27, 2025 4:00 PM EDTNovartis (NYSE: NVS) is set to report third-quarter results that Bank of America expects will be broadly in line with consensus, underpinned by strong prescription trends for key growth drivers.
According to BofA analyst Sachin Jain, the Neutral-rated drugmakers Q3 earnings per share are forecast at $2.30, up 12% year-on-year, on sales of about $14... More



